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Abstract: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system 
(CNS) characterized by an inappropriate inflammatory reaction resulting in widespread 
myelin injury along white matter tracts. Neurological impairment as a result of the disease 
can be attributed to immune-mediated injury to myelin, axons and mitochondria, but the 
molecular mechanisms underlying the neuropathy remain incompletely understood. 
Incomplete mechanistic knowledge hinders the development of therapies capable of 
alleviating symptoms and slowing disease progression in the long-term. Recently, 
oxidative stress has been implicated as a key component of neural tissue damage 
prompting investigation of reactive oxygen species (ROS) scavengers as a potential 
therapeutic option. Despite the establishment of oxidative stress as a crucial process in MS 
development and progression, ROS scavengers have had limited success in animal studies 
which has prompted pursuit of an alternative target capable of curtailing oxidative stress. 
Acrolein, a toxic β-unsaturated aldehyde capable of initiating and perpetuating oxidative 
stress, has been suggested as a viable point of intervention to guide the development of 
new treatments. Sequestering acrolein using an FDA-approved compound, hydralazine, 
offers neuroprotection resulting in dampened symptom severity and slowed disease 
progression in experimental autoimmune encephalomyelitis (EAE) mice. These results 
provide promise for therapeutic development, indicating the possible utility of neutralizing 
acrolein to preserve and improve neurological function in MS patients.  
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1. Introduction 
Multiple sclerosis (MS) is an autoimmune demyelinating neuropathy with a variety of endogenous 
and exogenous factors that are believed to influence disease risk and clinical course. Many reviews 
have focused on assessing patient susceptibility to MS, most notably relationships with gender, 
geography and genetics, which have demonstrated strong correlations in clinical cohort studies. 
However, to date, the molecular mechanisms underlying known pathogenic risk factors have yet to be 
established and, consequently, MS has remained largely refractory to available FDA-approved 
treatments. Marked progress in animal studies has enhanced understanding of pathological 
mechanisms allowing identification of novel therapeutic targets to improve quality and effectiveness of 
treatment regimens. Demonstrations of involvement of oxidative stress have led to attempts to 
sequester reactive oxygen species (ROS) for therapeutic intervention; however, to date, targeting 
solely ROS has had marginal success. This review summarizes current knowledge of MS pathogenesis 
focusing particularly on the role of acrolein, a toxic aldehyde and key factor in oxidative stress, in 
attempt to highlight the potential use of acrolein as a therapeutic target and a biomarker for MS 
diagnosis and disease progression. 
2. Pathogenesis 
Multiple sclerosis can be categorized into two main subtypes: relapsing remitting (RR) and primary 
progressive (PP), which differ in average age of onset, time course, and initial presentation [1]. RRMS, 
responsible for 85% of cases in predominantly younger patients, is characterized by one to two 
transient CNS attacks per year with either partial or complete symptomatic resolution. At an average 
age of 42 years, RRMS patients often transition to secondary progressive (SP) MS, a chronic phase 
characterized by attacks without recovery. Permanent neurological impairments of SPMS eventually 
provoke progressive physical deterioration of the patient [2,3]. The remaining 15% of cases typically 
present in older patients and are classified as PPMS [4]. PPMS shares many characteristics with 
SPMS, except that it is not preceded by RRMS; PPMS patients, even in initial stages of the disease, do 
not experience physical recovery following an attack.  
Although the exact molecular mechanisms remain to be elucidated, the general consensus is that the 
clinical features of MS are the result of a triad of neural tissue injury mechanisms: inflammation, 
demyelination, and axonal damage [2,5]. Autoreactive myelin-specific T-lymphocytes are considered 
the main inflammatory culprits behind nervous system assault and initiation of disease processes [5–8]. 
Presumed to be activated by molecular mimicry, these lymphocytes initiate a cascade of subsequent 
events such as blood-brain-barrier disruption, microglial activation, excitotoxicity, plaque 
development, and ultimately neurodegeneration and microglial scarring. Furthermore, evidence of 
inflammation is apparent in biopsied plaques comprised of lymphocytes and macrophages, and in the 
blood and CSF which include myelin reactive T-lymphocytes [9–11]. Microglia contribute to the 
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inflammatory atmosphere instigated by the T-cells by releasing proteolytic enzymes, cytokines, 
oxidative products, and free radicals all of which exhibit toxicity toward oligodendrocytes and  
myelin [1,3]. Inflammation elicits mitochondrial disruption, demyelination and axonal assault, the 
processes behind transient and permanent neurological impairment and conduction failure. In addition 
to myelin damage, axonal loss has also been recognized to contribute to the long term functional 
deficits and progression of disease [4,7,12,13]. Ultimately, compromise of axons, left vulnerable by 
loss of myelin sheath, is believed to elicit neuronal degeneration, cerebral atrophy, and permanent loss 
of function all of which are characteristic of late stage PPMS and SPMS.  
Traditional anti-inflammatory therapies have so far demonstrated short term effects in reducing 
relapse rates but little if any benefit in slowing disease progression [5,14]. Development of a novel and 
more effective treatment strategy necessitates additional study of the underlying pathogenic 
mechanisms. Establishment of well-defined links between the observed inflammatory reactions, 
demyelination, and axonal damage may enable identification of more suitable pharmacologic targets.  
3. Oxidative Stress 
Current studies have suggested that the pathogenic traits of MS collectively implicate oxidative 
stress as a crucial factor in initiating and perpetuating mechanisms responsible for the characteristic 
progressive neurological impairment [15–18]. Processes responsible for generation of reactive oxygen 
species and lipid peroxidation, hallmarks of oxidative stress, have been studied in attempt to develop 
therapies that can slow, halt, or even reverse chemically-mediated CNS damage. Recent efforts have 
focused on targeting ROS by applying pharmaceutical agents to curtail oxidative stress and suppress 
free radicals, likely instigators of demyelination and subsequent axonal degeneration. Unfortunately, 
these efforts have had minimal effect in vivo which is thought to be attributed to their short half-life, 
on the order of milliseconds, and degree of instability of ROS [5,14,18]. Limited response to 
application of ROS scavengers has led to the pursuit of a stable compound associated with oxidative 
stress to serve as a target for therapeutic intervention. Acrolein (2-propenal), a more stable compound 
capable of perpetuating oxidative stress by both initiating and bolstering lipid peroxidation and ROS 
generation, has been linked to a plethora of diseases [19–23]. Researchers have provided substantial 
data illustrating the detrimental nature of acrolein, particularly in the nervous system.  
4. Acrolein 
Acrolein, a β-unsaturated aldehyde, is a powerful toxin that has been shown to damage proteins, 
lipids, and DNA, generate free radicals, and activate cascades of noxious enzymes [17,24,25]. 
Acrolein has a variety of endogenous and exogenous sources. As a pollutant, acrolein is emitted during 
various manufacturing processes, burning cigarettes, exhaust from combustion engines, and vapors of 
overheated cooking oil [24]. Acrolein is also generated endogenously through the oxidation of various 
compounds, achieving pathological concentrations in conditions such as trauma, stress, and aging [26]. 
Both external and internal sources can elevate acrolein concentrations to potentially damaging levels 
within the body [17,27–31]. As both a product and catalyst of lipid peroxidation, acrolein induces a 
vicious cycle of oxidative stress, dramatically amplifying its effects [24,32]. Furthermore, acrolein 
remains active in the body much longer than commonly studied oxidative species; most oxygen 
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radicals decay within fractions of a second, while acrolein persists for seven to ten days [33]. 
Compared to other aldehydes associated with oxidative stress such as 4-hydroxynonenal, acrolein is 
generated at 40 times greater concentration and is 100 times more reactive [24,32,33]. Therefore, 
acrolein is the most reactive and abundant aldehyde. This evidence strongly suggests that acrolein is a 
key factor in perpetuating oxidative stress and has the potential to serve as a viable therapeutic target. 
Studies have demonstrated that acrolein is capable of directly damaging nucleic acids present in 
DNA, amino acids and lipids, all crucial components of myelin sheath and the lipid-rich neuronal 
membrane. Through reaction with a wide variety of proteins and GSH, acrolein adducts have also 
exhibited significant reactivity and a longer half-life than that of free acrolein. Furthermore, a recent 
study has demonstrated that sequestering acrolein in an animal model of MS, through the use of 
acrolein scavengers, promotes functional recovery and decreases incidence of demyelination [27]. As 
evidenced in the aforementioned study, acrolein is likely a key mediator in sustaining or even further 
aggravating the inflammatory environment presumably liable for functional deterioration in MS and an 
assortment of other diseases attributed to oxidative stress [27]. An increase in acrolein-lysine adduct 
level was observed in EAE mice concordantly with the presence of behavioral deficit. In addition, 
treatment with an acrolein scavenger, hydralazine, reduced demyelination, slowed disease progression 
and improved behavioral score [27]. These studies further implicate acrolein as a pathologic factor in 
MS by demonstrating the attenuation of behavioral deficit and myelin damage in response to 
neutralizing acrolein with hydralazine.  
5. Demyelination 
CNS demyelination, the hallmark of MS development and progression, is responsible for the 
characteristic transient functional impairment seen clinically in RRMS [5,14]. Nerve conduction is 
adversely affected by myelin loss due to increased energy required for action potential propagation. 
Ultimately, increased energy expenditure depletes ATP and if myelin integrity is not restored, impulse 
conduction is halted. Previous evidence has indicated that myelin also plays an integral role in 
localizing expression of voltage-gated sodium (VGNa) to the nodes of Ranvier and voltage-gated 
potassium (VGK) channels to the juxtaparanodal region beneath myelin sheath. Decompaction or 
degradation of myelin results in the aberrant channel expression in which both VGNa and VGK 
channels are distributed along the entire length of the axon. VGNa channel redistribution is considered 
a compensatory mechanism permitting temporary preservation of conduction despite myelin 
breakdown and compromised nodes of Ranvier. However, VGNa channel rearrangement ultimately 
becomes ineffective, leading to an ionic imbalance and extracellular calcium influx, which is further 
exacerbated by VGK channel migration from the juxtaparanodal region. In addition, aberrant VGK 
expression resulting from acrolein-mediated myelin retraction can cause inappropriate outward 
movement of potassium ions and the failure of action potential generation at nodal region [34–36].  
It is known that acrolein can directly damage myelin, likely through reaction with the protein and 
lipid components of the myelin sheath [27,35,37]. Specifically, when isolated ex vivo spinal cord was 
exposed to acrolein, significant alterations in myelin structure were observed including myelin 
retraction from the nodes of Ranvier and myelin splitting or decompaction [35]. Consequently, myelin 
retraction exposed VGK in the juxtaparanodal region, a well-established mechanism that culminates in 
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conduction failure. Increased expression of VGK was reported to extend beyond the juxtaparanodal 
region into the nodes of Ranvier when exposed to acrolein for up to12 h [35,38]. It is hypothesized that 
localized expression of VGK is dictated by axoglial septate junctions. When acrolein-mediated 
damage at the junction damages anchoring proteins, channel movement is no longer inhibited 
facilitating aberrant VGK expression within the nodal region. Evidence supporting the notion of 
acrolein-mediated damage of axoglial septate junctions is that Caspr, an anchoring protein expressed in 
the paranodal region of healthy neurons, is delocalized following acrolein exposure [35,36]. In 
addition to directly reacting with myelin constituents, acrolein exposure activates calpain, an enzyme 
involved in microtubule degradation, enhancing the already toxic environment [39–41].  
Though demyelination and membrane damage were previously considered separate disease 
processes, they now appear to be intertwined; both have an impact on ionic balance and channel 
distribution essential for usual axonal conduction [42–45]. Disruption of these two components by 
acrolein is likely to be at least partly responsible for the symptoms and functional deterioration 
observed in MS patients. This hypothesis is supported by the fact that acrolein is capable of damaging 
both myelin and axons directly and indirectly. Myelin retraction and loss alters the activity and induces 
aberrant expression of many ion channels resulting in conduction failure and functional decline. 
Concordantly, axonal damage also leads to conduction failure and neuronal degeneration, and, in 
addition, permanent neurological dysfunction characteristic of PP- and SP-MS. Therefore, it is 
reasonable to suggest the role of acrolein in dual pathological processes in MS.  
6. Axonal Injury 
The importance of axonal degeneration as a pathologic mechanism in MS has been demonstrated by 
post-mortem studies that directly examined lesions in MS patient brain tissue using markers for axonal 
damage and myelin disruption. These studies observed a great number of transected axons, implicating 
axonal injury as a critical feature of neurodegeneration likely responsible for permanent neurological 
deficit often seen in late stages of MS [13,46]. This idea is further supported by the evidence that 
axonal damage provoked by an inflammatory environment results in conduction failure and subsequent 
symptom development in MS animal models and clinical cases [2,47]. Furthermore, axonal injury 
likely represents permanent neuron impairment, and ultimately degeneration, serving as a likely 
explanation for absence of functional recovery in PP- and SP-MS [13,46]. In instances of axonal 
damage in demyelinated axons, atypical expression of glutamate receptors, sodium channels, and 
voltage-gated calcium channels has been reported [17,25]. These results indicate that axonal injury 
coupled with altered channel expression, resulting from myelin decompaction, may increase 
intracellular calcium levels, all contributing to the degeneration of axons.  
As mentioned, acrolein is capable of inflicting axonal damage directly. This is likely because the 
axonal membrane, like myelin, is lipid rich and therefore equally susceptible to oxidative  
insult—especially acrolein attack. On the other hand, demyelination not only impairs conduction 
through loss of internodes and aberrant channel expression, but also leaves the axonal membrane 
exposed and vulnerable to injury by inflammatory mediators released by activated glial cells, and 
acrolein. Taken together, acrolein can damage axons through direct and indirect mechanisms.  
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Shi and colleagues have demonstrated that micromolar concentrations of acrolein can disrupt the 
lipid rich cellular membrane, and, moreover, elevated acrolein levels are accompanied by observable 
increase of axonal permeability and loss of compound action potential (CAP) conduction [17,30,48]. 
Introduction of a known acrolein scavenger, hydralazine, in an in vivo or in vitro model was able to 
alleviate axonal damage. These studies have provided compelling evidence that acrolein is indeed 
capable of inflicting axonal damage and likely plays a significant role in axonal loss in an MS animal 
model [27].  
7. Mitochondrial Dysfunction 
Mitochondrial impairment is an important mechanism underlying observed deficits characteristic of 
MS causing deficient energy production provoking cell death. Demyelination and axonal membrane 
compromise lead to calcium influx, with consequent activation of cellular pathways provoking harmful 
mediators that directly attack mitochondria [14]. The hostile inflammatory environment and membrane 
deterioration associated with oxidative stress suggest that mitochondria may also be vulnerable to the 
effects of acrolein and ROS more than other cellular structures. Mitochondria provide energy to the 
cell in the form of ATP to promote cell function, growth and survival. The process by which they are 
able to generate energy, results in the non-pathological production of ROS by the electron transport 
chain. Mitochondrial dysfunction impairs the ability of neurons to combat oxidative stress and allows 
the release of endogenous ROS produced by the mitochondria. Thus, in disease states, mitochondria 
are particularly susceptible to the damaging effects of oxidative compounds and furthermore can 
exacerbate oxidative stress and promote cell death and subsequent axonal loss [49,50].  
Acrolein has been shown to cause dysfunction of mitochondrial respiration in heart, spinal cord and 
brain tissues [25,51–53]. Recently, evidence has been obtained revealing that acrolein may be able to 
directly damage mitochondria. Specifically, it has been demonstrated that isolated mitochondria, when 
exposed to acrolein, generate ROS and deplete GSH [25]. Reduction of GSH by acrolein renders brain 
mitochondria highly susceptible to oxidative stress due to their low levels of catalase [25]. The notion 
of direct attack of mitochondria by acrolein was further strengthened by the fact that acrolein impairs 
adenine nucleotide translocase (ANT) and consequently, the electron transport chain. It was  
suggested that acrolein can directly inhibit ANT, likely through binding cysteine residues, ultimately 
diminishing local energy production, perpetuating oxidative stress, and severely impairing 
mitochondria function [25,54,55]. This hypothesis is supported by evidence that dysfunction of the 
electron transport chain can be facilitated by inhibition of ANT and depletion of glutathione by increased 
mitochondrial ROS production [56–58]. If these mechanisms are indeed valid, acrolein would be capable 
of both inhibition of ANT and stimulation of ROS production within mitochondria [25]. 
8. Acrolein Scavenging—A Novel Treatment Strategy for MS 
Since acrolein has been implicated as a factor capable of instigating and perpetuating the main 
pathogenic mechanisms underlying MS, it is a logical target for pharmacologic therapeutic targeting. 
Compounds capable of binding and neutralizing acrolein have shown great promise by alleviating 
elevated acrolein levels and attenuating functional decline in EAE mice [42]. Some drugs currently 
being examined, such as hydralazine, an FDA-approved anti-hypertensive, are show to be effective 
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acrolein scavengers in both in vitro and in vivo studies at safe doses [27,48,59]. When administered to 
EAE mice in doses that are substantially less than those approved clinically for antihypertensive use, 
hydralazine is capable of sequestering acrolein, mitigating behavioral decline and alleviating 
demyelination seen in histological preparations [27]. Similar beneficial effects were also seen in SCI 
where acrolein has been implicated. Considering the ability to scavenge acrolein and its  
FDA-approval, we speculate that the hydralazine-based anti-acrolein strategy could be developed into 
a new MS therapy that can be rapidly translated into the clinic.  
Ideally, application of acrolein-scavenging drugs would ease motor deficit through reduction of 
acrolein-associated oxidative stress and subsequent membrane, myelin and mitochondrial insult and 
ultimately be translated to the clinic as a viable treatment available for MS patients. The main 
advantage of this novel approach includes a clear, identifiable, molecular target for treatment, 
established methods of monitoring acrolein levels for potential diagnosis, treatment selection and 
evaluation. Beyond amplifying oxidative stress, acrolein synergistically exacerbates other parallel 
pathologies that are potentially involved in MS pathology, such as ischemia, inflammation, and 
excitotoxicity [60–65]. Therefore, once established anti-acrolein therapies could also be paired with other 
interventions to maximize treatment effects and greatly enhance the quality of life for MS patients. 
9. Concluding Remarks 
There is strong evidence to support that oxidative stress plays a role in course of MS and symptom 
development. Acrolein appears to be the key factor perpetuating oxidative stress. Recent studies have 
ascertained that ROS and acrolein are at least partially responsible for the three hallmark mechanisms 
underlying the disease: axonal membrane damage, demyelination, and mitochondrial dysfunction. 
More specifically, acrolein is capable of damaging the membrane, myelin, and mitochondria in the 
nervous system. Elevated levels of acrolein have been detected in CNS tissue in EAE mice when 
symptoms peak. In addition, the acrolein scavenger, hydralazine, has been shown to reduce symptom 
severity and slow disease progression through a different mechanism than the currently approved 
treatments. This information provides compelling evidence supporting the role of acrolein in 
functional deterioration and characteristic mechanisms associated with MS. Therefore, acrolein may 
contribute to the pathogenesis of the disease and has the potential to serve as a novel target for the 
effective use of acrolein scavengers for long-term symptomatic improvement in MS patients. 
Furthermore, this strategy may also be efficacious in the treatment of other diseases associated with 
oxidative stress such as cancer, diabetes, atherosclerosis, SCI, and other neurodegenerative disorders.  
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